New Reports Cite Science Priorities

The same decision-making process was displayed by Fisher's Council of Competitiveness,which was formed in 1986 by a group of prominent leaders from industry and academia. Instead of requesting more for research, the council asked Congress to take the billions now going into what it called "national prestige technology projects," such as the space station, the superconducting supercollider, the Hubble space telescope, the national aerospace plane, and the Human Genome Project, and put them into

Written byJeffrey Mervis
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The same decision-making process was displayed by Fisher's Council of Competitiveness,which was formed in 1986 by a group of prominent leaders from industry and academia. Instead of requesting more for

research, the council asked Congress to take the billions now going into what it called "national prestige technology projects," such as the space station, the superconducting supercollider, the Hubble space telescope, the national aerospace plane, and the Human Genome Project, and put them into smaller efforts that promise a quicker economic return.

"That list could be expanded without much trouble," says Fisher. "We think it's time to look at these big-time projects and ask if their rate of development should be slowed." The council also asked the government to apply new criteria in making decisions about funding big science. "In allocating resources to its science and technology programs," the report suggests, "the government should consider the magnitude of the potential ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies